Delfritama Ibadillah

Delfritama Ibadillah

Auto-generated profile, based on publicly available information

Delfritama Ibadillah

Center of Excellence Life Sciences, Nano Center Indonesia, South Tangerang, Indonesia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2024 in ADMET and DMPK
Verified
Journal Article
Open access
PDF file
Paula Mariana KustiawanPaula Mariana Kustiawan
Paula Mariana Kustiawan
PSPutri Hawa Syaifie
Putri Hawa Syaifie
KSKhalish Arsy Al Khairy Siregar
Khalish Arsy Al Khairy Siregar
DIDelfritama Ibadillah
Delfritama Ibadillah
EMEtik Mardliyati
Etik Mardliyati
Background and purpose: Scientific research is crucial to develop therapies for various disease severity levels, as modern drugs cause side effects and are difficult to predict. Researchers are exploring herbal alternatives with fewer side effects, particularly propolis, which has been validated through in vitro, in vivo, and clinical studies. This will focus on scientific evidence and its supporting technology for developing new bioactive compounds for chronic diseases. Nanotechnology can improve the delivery and absorption of herbal medicines, which often have poor bioavailability due to their high molecular weight and solubility in water, particularly in oral medicines. This technology can enhance propolis's effects through multi-target therapy and reduce side effects. Experimental approach: All publications related to each section of this review were discovered using the search engines Google Scholar, Scopus, and Pubmed. This was only available for publication between 2013 and 2023. The selected publications were used as references in this review after being thoroughly studied. Key results: Evaluation of propolis active compounds, the classification of propolis nano formulations, design concepts, and mechanisms of action of propolis nano formulation. Additionally, the challenges and prospects for how these insights can be translated into clinical benefits are discussed. Conclusion: In the last ten years, a list of nanoformulation propolis has been reported. This review concludes the difficulties encountered in developing large-scale nanoformulations. To commercialize them, improvements in nano carrier synthesis, standardized evaluation methodology within the framework of strategy process improvement, and Good Manufacturing Practices would be required.

25 June 2024 in Heliyon
Verified
Journal Article
Open access
Paula Mariana KustiawanPaula Mariana Kustiawan
Paula Mariana Kustiawan
KSKhalish Arsy Al Khairy Siregar
Khalish Arsy Al Khairy Siregar
PSPutri Hawa Syaifie
Putri Hawa Syaifie
FMFauzan Zein Muttaqin
Fauzan Zein Muttaqin
DIDelfritama Ibadillah
Delfritama Ibadillah
NRNurul Taufiqu Rochman
Nurul Taufiqu Rochman
Numerous side effects of breast cancer drugs have prompted researchers to explore more into new therapeutic approaches derived from natural substances. In this context, our study focused on uncovering the potential of East Kalimantan propolis from Trigona apicalis for breast cancer treatment including the underlying mechanisms through bioinformatics approached. We conducted integrated in vitro and bioinformatics analysis of network pharmacology, molecular docking, molecular dynamics and MM-GBSA analysis. Initially, in vitro cytotoxic assay demonstrated the anti-breast cancer activity potential of ethanol extract of East Kalimantan propolis, particularly its ethyl acetate fraction, which exhibited similar activity to doxorubicin, as indicated by their IC50 value. This study revealed eight propolis compounds, consisting of flavonoids and phenolic acids, in East Kalimantan propolis. By integrating microarray datasets (GSE29431, GSE36295, and GSE42568) analysis with potential targets derived from propolis compounds, 39 shared target genes were identified. Subsequently, GO and KEGG pathway, protein–protein interaction (PPI) network, core hub genes and gene expression analysis revealed three major targets, namely, PTGS2, CXCL2, and MMP9. Among them, only MMP9 was highly expressed in breast cancer than normal. Moreover, molecular docking revealed the six of propolis compounds which exhibited pronounced binding affinity towards MMP-9, better than marimastat as control drug. Dynamic simulation confirmed the stability of chrysin and quercetin as best compounds. Additionally, MM-GBSA analysis revealed a relative binding energy for chrysin (−25.6403 kcal/mol) that was comparable to marimastat (−27.3827 kcal/mol). In conclusion, this study reveals how East Kalimantan Propolis affect breast cancer and emphasizes MMP9 as a key target for future therapeutics.